Zydus Cadila Midodrine Hydrochloride tablets get USFDA okay to treat orthostatic hypotension
Midodrine Hydrochloride tablets will be manufactured at Zydus Cadila's formulation manufacturing facility at SEZ, Ahmedabad.
Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Midodrine Hydrochloride Tablets (US RLD- ProAmatine Tablets) in the strengths of 2.5 mg, 5 mg, and 10 mg.
The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension.
The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 298 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Next Story
